Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis

• Published in: Frontiers in endocrinology (Lausanne) Vol. 13; p. 850836
• Main Authors: Wei, Wen, Liu, Jin, Chen, Shiqun, Xu, Xinghao, Guo, Dachuan, He, Yibo, Huang, Zhidong, Wang, Bo, Huang, Haozhang, Li, Qiang, Chen, Jiyan, Chen, Hong, Tan, Ning, Liu, Yong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.03.2022
• Subjects: cardiorenal outcomes; coronary artery disease; Coronary Artery Disease - complications; Coronary Artery Disease - drug therapy; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Endocrinology; Heart Failure - complications; Humans; improve; meta-analysis; sodium glucose cotransporter type 2 inhibitors; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; coronary artery disease; meta-analysis; improve; sodium glucose cotransporter type 2 inhibitors; cardiorenal outcomes

Sodium glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), heart failure (HF) or chronic kidney disease (CKD). However, whether or not the patients with coronary artery disease (CAD) have prognostic benefit from...